Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stemcelline Vial – UC Xeno-Free Mesenchymal cells
- Development stage
- Unknown
- Lead developer
- Stemcelline
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intracoronary, Intramyocardial, Transendocardial, Transpericardial, Intraarticular, Intrathecal, Perineural, Intranasal, Inhalation, Rectal, Subcutaneous
01
Overview
Stemcelline Vial – UC Xeno-Free Mesenchymal cells is an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy developed by the Indian biotechnology company Stemcelline. The product is manufactured using xeno-free culture conditions to ensure high purity and reduce the risk of immunogenic reactions associated with animal-derived components. It is currently in Phase 1 clinical development for the treatment of respiratory conditions, including bronchopulmonary dysplasia (BPD) and chronic obstructive pulmonary disease (COPD). The therapeutic mechanism is based on the innate ability of MSCs to migrate to damaged tissues and exert immunomodulatory and regenerative effects through the secretion of various paracrine factors, which help to mitigate inflammation and promote the repair of lung tissue.
- Brand names
- Stemcelline Vial
- Other names
- UC-MSCUmbilical Cord-derived Mesenchymal Stem CellsUC Xeno-Free Mesenchymal cells
Beyond the preview
Go deeper on Stemcelline Vial – UC Xeno-Free Mesenchymal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stemcelline Vial – UC Xeno-Free Mesenchymal cells.